CA-ESRI
10.3.2022 14:02:10 CET | Business Wire | Press release
Governments and businesses across the world are pledging to adopt more sustainable and equitable practices. Many are also working to limit activities that contribute to climate change. To support these efforts, Esri , the global leader in location intelligence, in partnership with Impact Observatory and Microsoft, is releasing a globally consistent 2017–2021 global land-use and land-cover map of the world based on the most up-to-date 10-meter Sentinel-2 satellite data. In addition to the new 2021 data, 10-meter land-use and land-cover data for 2017, 2018, 2019, and 2020 is included, illustrating five years of change across the planet.
This digital rendering of earth's surfaces offers detailed information and insights about how land is being used. The map is available online to more than 10 million users of geographic information system (GIS) software through Esri's ArcGIS Living Atlas of the World , the foremost collection of geographic information and services, including maps and apps.
"Accurate, timely, and accessible maps are critical for understanding the rapidly changing world, especially as the effects of climate change accelerate globally," said Jack Dangermond, Esri founder and president. "Planners worldwide can use this map to better understand complex challenges and take a geographic approach to decisions about food security, sustainable land use, surface water, and resource management."
Esri released a 2020 global land-cover map last year as well as a high-resolution 2050 global land-cover map , showing how earth's land surfaces might look 30 years from now. With the planned annual releases, users will have the option to make year-to-year comparisons for detecting change in vegetation and crops, forest extents, bare surfaces, and urban areas.
These maps also provide insights about locations with distinctive land use/land cover, as well as human activity affecting them. National government resource agencies use land-use/land-cover data as a basis for understanding trends in natural capital, which helps define land-planning priorities and determine budget allocations.
Esri's map layers were developed with imagery from the European Space Agency (ESA) Sentinel-2 satellite, with machine learning workflows by Esri Silver partner Impact Observatory and incredible compute resources from longtime partner Microsoft. The Sentinel-2 satellite carries a range of technologies including radar and multispectral imaging instruments for land, ocean, and atmospheres, enabling it to monitor vegetation, soil and water cover, inland waterways, and coastal areas.
"World leaders need to set and achieve ambitious targets for sustainable development and environmental restoration," said Steve Brumby, Impact Observatory cofounder and CEO. "Impact Observatory [and] our partners Esri and Microsoft are once again first to deliver an annual set of global maps at unprecedented scale and speed. These maps of changing land use and land cover provide leaders in governments, industry, and finance with a new AI [artificial intelligence]-powered capability for timely, actionable geospatial insights on demand."
Esri and Microsoft have released this 10-meter-resolution time-series map under a Creative Commons license to encourage broad adoption and ensure equitable access for planners working to create a more sustainable planet. Users can manipulate the map layers and other data layers with GIS software to create more dynamic visualizations.
In addition to being freely available in ArcGIS Online as a map service, these resources are also available for download and viewing. To explore the new 2021 global land-use/land-cover map, visit livingatlas.arcgis.com/landcover .
About Impact Observatory
Impact Observatory develops AI-powered, on-demand, geospatial data that maps changing land use and land cover at unprecedented scale and speed. Impact Observatory provides world leaders in governments, industry, and finance with timely, actionable, data-driven insights for sustainability and environmental risk analysis. Impact Observatory is a U.S. technology company based in Washington, D.C.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2022 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005316/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom